JAK
JAK (Janus kinase) inhibitors are compounds that target the JAK-STAT signaling pathway, which is involved in cell growth, immune response, and angiogenesis. By inhibiting JAK, these compounds can reduce the signaling that leads to the formation of new blood vessels in tumors, thereby inhibiting tumor growth. JAK inhibitors are important in the treatment of cancers and inflammatory diseases. At CymitQuimica, we offer a diverse range of high-quality JAK inhibitors to support your research in oncology, immunology, and angiogenesis.
Found 245 products of "JAK"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Ilunocitinib
CAS:<p>Ilunocitinib is a non-selective and orally active Janus kinase (JAK) inhibitor for pruritus and atopic dermatitis caused by atopic dermatitis in dogs.</p>Formula:C17H17N7O2SPurity:99.88%Color and Shape:SolidMolecular weight:383.43Ifidancitinib
CAS:<p>Ifidancitinib (ATI-50002) is a JAK kinase 1/3 inhibitor used to study autoimmune diseases.</p>Formula:C20H18FN5O3Purity:98.05%Color and Shape:SolidMolecular weight:395.39Atinvicitinib
CAS:<p>Atinvicitinib, a selective JAK1 inhibitor, blocks cytokine signaling, modulating itch, allergy, and inflammatory responses, immune and therapeutic studies.</p>Formula:C16H17FN6O3Purity:99.36%Color and Shape:SolidMolecular weight:360.35CHZ868
CAS:<p>CHZ868 is a type II JAK inhibitor with potential antitumor activity that reverses the persistence of type I JAK inhibitors and can be used to study leukemia.</p>Formula:C22H19F2N5O2Purity:99.38%Color and Shape:SolidMolecular weight:423.42WHI-P154
CAS:Formula:C16H14BrN3O3Purity:>98.0%(HPLC)Color and Shape:White to Yellow to Orange powder to crystalMolecular weight:376.21Itacitinib adipate
CAS:<p>Itacitinib adipate: oral JAK1 inhibitor, tested in phase II myelofibrosis trial.</p>Formula:C32H33F4N9O5Color and Shape:SolidMolecular weight:699.66WHI-P180 Hydrochloride
CAS:Formula:C16H15N3O3·HClPurity:>97.0%(T)(HPLC)Color and Shape:White to Light gray to Light yellow powder to crystalMolecular weight:333.77DTP3
CAS:<p>DTP3 is a selective MKK7/GADD45β inhibitor, which inhibits cancer-selective NF-κB survival pathway.</p>Formula:C26H35N7O5Color and Shape:SolidMolecular weight:525.6PF-06651600 malonate
CAS:<p>PF-06651600 is a potent and selective JAK3 inhibitor.</p>Formula:C18H23N5O5Color and Shape:SolidMolecular weight:389.41Fedratinib hydrochloride hydrate
CAS:<p>Fedratinib hydrochloride hydrate (SAR 302503 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor.</p>Formula:C27H40Cl2N6O4SPurity:98.96% - 99.87%Color and Shape:SolidMolecular weight:615.61AG490
CAS:<p>AG490 inhibits EGFR (0.1 μM IC50), 135x > selective than ErbB2, blocks JAK2, spares Lyn, Lck, Syk, Btk, Src.</p>Formula:C17H14N2O3Purity:98.6% - 99.39%Color and Shape:Yellow SolidMolecular weight:294.3Abrocitinib
CAS:<p>Abrocitinib (PF-04965842) (PF-04965842) is a potent, specific and orally-active JAK1 inhibitor (IC50s: 29/803 nM for JAK1/2).</p>Formula:C14H21N5O2SPurity:99.09% - 99.91%Color and Shape:SolidMolecular weight:323.41CEP-33779
CAS:<p>CEP-33779 is a novel and selective inhibitor of JAK2 with an IC50 of 1.8±0.6 nM.</p>Formula:C24H26N6O2SPurity:98.24% - ≥95%Color and Shape:SolidMolecular weight:462.57SHR0302
CAS:<p>SHR0302 (ARQ252) is a JAK inhibitor that binds JAK1 with stronger affinity than others (Selectivity for JAK1 is more than 10 times for JAK2, 77 times for JAK3,</p>Formula:C18H22N8O2SPurity:99.11%Color and Shape:SolidMolecular weight:414.48BD750
CAS:<p>BD750 is an effective immunosuppressant and a JAK3/STAT5 inhibitor, inhibits IL-2-induced JAK3/STAT5-dependent T cell proliferation(IC50 of 1.5 μM and 1.1 μM in</p>Formula:C14H13N3OSPurity:99.02%Color and Shape:SolidMolecular weight:271.34Gandotinib
CAS:<p>LY2784544(Gandotinib (LY2784544)) is a potent JAK2 inhibitor (IC50: 3 nM), effective in JAK2V617F(Ki: 0.245 nM).</p>Formula:C23H25ClFN7OPurity:99.33% - 99.86%Color and Shape:SolidMolecular weight:469.94Ritlecitinib tosylate
CAS:<p>Ritlecitinib (PF-06651600) is a potent, selective JAK3 inhibitor with proven in vivo efficacy, low clearance, and has undergone clinical trials.</p>Formula:C22H27N5O4SColor and Shape:SolidMolecular weight:457.5492,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide
CAS:<p>2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide (GDC046), a potent lead analog, has good kinase selectivity and physicochemical properties.</p>Formula:C16H13Cl2N3O2Purity:98.77%Color and Shape:SolidMolecular weight:350.2AT9283
CAS:<p>AT9283 (J-504568) is an effective multi-targeted inhibitor of JAK2(IC50=1.2 nM) and JAK3(IC50=1.1 nM), Aurora A, Aurora B and Abl(T315I).</p>Formula:C19H23N7O2Purity:99.83% - 99.98%Color and Shape:SolidMolecular weight:381.43Pacritinib hydrochloride
CAS:<p>Pacritinib HCl: strong JAK2/Wild-type & JAK2V617F inhibitor (IC50: 23/19 nM), used in AML & MF research.</p>Formula:C28H32N4O3·xClHColor and Shape:SolidCurculigoside
CAS:<p>1.</p>Formula:C22H26O11Purity:99.85%Color and Shape:SolidMolecular weight:466.44Tofacitinib Citrate
CAS:<p>Tofacitinib Citrate (CP-690550 citrate) is a a potent, cell-permeable inhibitor of JAK1/2/3 (IC50s: 1/20/112 nM).</p>Formula:C22H28N6O8Purity:99.19% - 99.75%Color and Shape:SolidMolecular weight:504.49Ruxolitinib phosphate
CAS:<p>Ruxolitinib phosphate (INCB18424 phosphate) is a JAK1/2 inhibitor with IC50 of 3.3 nM/2.8 nM. Cost-effective and quality-assured.</p>Formula:C17H21N6O4PPurity:98% - >99.99%Color and Shape:SolidMolecular weight:404.36GLPG0634 analog
CAS:<p>GLPG0634 analog (GLPG0634 analogue) is a specific JAK1 inhibitor with IC50 of 10/28/810/116 nM for JAK1/2/3 and TYK2, respectively.</p>Formula:C23H18N6O2Purity:99.52% - >99.99%Color and Shape:SolidMolecular weight:410.43FLLL32
CAS:<p>FLLL32 is an effective JAK2/STAT3 inhibitor (IC50 of <5 μM).</p>Formula:C28H32O6Purity:97% - 97.90%Color and Shape:SolidMolecular weight:464.55G5-7
CAS:<p>G5-7 is an oral JAK2 inhibitor targeting EGFR/STAT3 phosphorylation with potential for glioma research.</p>Formula:C22H19F2NO3Purity:97.3%Color and Shape:SolidMolecular weight:383.39GDC-0214
CAS:<p>GDC-0214 is an inhaled small-molecule JAK1 inhibitor and reduces fractional exhaled nitric oxide (Feno).</p>Formula:C28H28ClF2N9O3Purity:99.75%Color and Shape:SolidMolecular weight:612.03AMG-47a
CAS:<p>AMG-47a inhibits Lck, T cell growth, and degrades KRAS oncoprotein, affecting EGFP-KRASG12V but not EGFP.</p>Formula:C29H28F3N5O2Purity:98%Color and Shape:SolidMolecular weight:535.56AZ960
CAS:<p>AZ960 is an effective ATP competitive JAK2 inhibitor (IC50/Ki: <3 nM and0.45 nM).</p>Formula:C18H16F2N6Purity:96.02% - 98.51%Color and Shape:SolidMolecular weight:354.36Decernotinib
CAS:<p>Decernotinib (VRT-831509)(VX-509; VRT-831509) is a potent and selective Janus kinase 3 (JAK3) inhibitor with Ki of 2.5 nM; IC50 is 50-170 nM in cellular assays.</p>Formula:C18H19F3N6OPurity:99.28% - >99.99%Color and Shape:SolidMolecular weight:392.38Baricitinib
CAS:<p>Baricitinib (INCB028050) is an orally JAK1 and JAK2 inhibitor. Baricitinib has anti-inflammatory and anti-tumor activity. Cost-effective and quality-assured.</p>Formula:C16H17N7O2SPurity:99% - >99.99%Color and Shape:SolidMolecular weight:371.42JAK3-IN-6
CAS:<p>JAK3-IN-6 is irreversible Janus Associated Kinase 3 (JAK3) inhibitor, with an IC50 of 0.15 nM</p>Formula:C19H18N4O3Purity:99.94% - 99.94%Color and Shape:SolidMolecular weight:350.37Ruxolitinib (S enantiomer)
CAS:<p>Ruxolitinib S enantiomer (INCB18424) is the S-enantiomer of Ruxolitinib. Ruxolitinib is the first potent, selective JAK1/2 inhibitor.</p>Formula:C17H18N6Purity:99.37% - 99.79%Color and Shape:SolidMolecular weight:306.36WHI-P97 HCl
<p>WHI-P97 HCl is a potent and selective JAK-3 inhibitor.</p>Formula:C16H14Br2ClN3O3Purity:99.49%Color and Shape:SolidMolecular weight:491.56Fedratinib
CAS:<p>Fedratinib (TG-101348) (TG101348) is an ATP-competitive inhibitor of JAK2 (IC50: 3 nM) with significantly less potent activity against JAK3.</p>Formula:C27H36N6O3SPurity:97.31% - 99.96%Color and Shape:SolidMolecular weight:524.68RO495
CAS:<p>RO495 (CS-2667), a potent inhibitor of TYK2, inhibits TYK2 with IC50 of 1.5nM as tested in cell-based pharmacological assays</p>Formula:C17H14Cl2N6OPurity:97.94%Color and Shape:SolidMolecular weight:389.24WP1066
CAS:<p>WP1066 is a inhibitor of JAK2 (IC50: 2.30 μM) and STAT3 (IC50: 2.43 μM) in HEL cells; shows activity to JAK2, STAT3/5, and ERK1/2, not JAK1 and JAK3.</p>Formula:C17H14BrN3OPurity:98.92% - 99.73%Color and Shape:SolidMolecular weight:356.22Momelotinib HCl
CAS:<p>Momelotinib HCl is a JAK1/2 inhibitor, reducing anemia in myelofibrosis (MF) patients.</p>Formula:C23H24Cl2N6O2Color and Shape:SolidMolecular weight:487.38RGB-286638 free base
CAS:<p>RGB-286638 free base inhibits CDKs (1-5 nM), weaker on CDK7/6.</p>Formula:C29H35N7O4Purity:98% - 99.91%Color and Shape:SolidMolecular weight:545.63SC99
CAS:<p>SC99 inhibits JAK2-STAT3, reducing STAT3 genes, platelet activity, and has anti-myeloma, anti-thrombotic effects.</p>Formula:C15H8Cl2FN3OPurity:99.56%Color and Shape:SolidMolecular weight:336.15Pyridone 6
CAS:<p>Pyridone 6, a selective JAK1/2/3 and Tyk2 inhibitor with IC50s: JAK1=15 nM, JAK2=1 nM, JAK3 (Ki=5 nM), Tyk2=1 nM; weakly binds other kinases (130 nM-10 μM).</p>Formula:C18H16FN3OPurity:97.1% - 98.74%Color and Shape:SolidMolecular weight:309.34NVP-BSK805 trihydrochloride
CAS:<p>NVP-BSK805 trihydrochloride inhibits JAK2 (0.48 nM IC50); also affects JAK1, JAK3, TYK2.</p>Formula:C27H31Cl3F2N6OColor and Shape:SolidMolecular weight:599.93Ritlecitinib
CAS:<p>Ritlecitinib (PF-06651600) is an orally available, selective JAK3 inhibitor and does not affect the activity of JAK1/2.Cost-effective and quality-assured.</p>Formula:C15H19N5OPurity:98.82% - 99.92%Color and Shape:SolidMolecular weight:285.34(E/Z)-Zotiraciclib
CAS:<p>(E/Z)-Zotiraciclib ((E/Z)-TG02) inhibits CDK2, JAK2, and FLT3 effectively with IC50s of 13, 73, and 56 nM, respectively.</p>Formula:C23H24N4OPurity:97.75% - 99.92%Color and Shape:SolidMolecular weight:372.46Deucravacitinib
CAS:<p>Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable, allosteric TYK2 inhibitor.Cost-effective and quality-assured.</p>Formula:C20H19D3N8O3Purity:98.52% - >99.99%Color and Shape:SolidMolecular weight:425.46WDR5-0103 hydrochloride[890190-22-4(free base)]
<p>WDR5-0103 hydrochloride[890190-22-4(free base)] (WD-Repeat Protein 5-0103) is an effective and specific WD repeat-containing protein 5 (WDR5) antagonist (Kd:</p>Formula:C21H26ClN3O4Purity:99.66%Color and Shape:SolidMolecular weight:419.9XL019
CAS:<p>XL019 is a potent and selective JAK2 inhibitor with IC50 of 2.2 nM, 100 fold selectivity over JAK1.</p>Formula:C25H28N6O2Purity:99.19%Color and Shape:SolidMolecular weight:444.53TG101209
CAS:<p>TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM.</p>Formula:C26H35N7O2SPurity:99% - >99.99%Color and Shape:SolidMolecular weight:509.67Brevilin A
CAS:<p>Brevilin A, a sesquiterpene from Centipeda minima, hinders JAK and blocks STAT3 (IC50=10.6μM), inducing apoptosis and autophagy in cancer cells.</p>Formula:C20H26O5Purity:99.97% - >99.99%Color and Shape:SolidMolecular weight:346.42FM-381
CAS:<p>FM381, a JAK3 inhibitor with 127 pM IC50, is 410-3600x more selective over JAK1/2/TYK2.</p>Formula:C24H24N6O2Purity:98.44%Color and Shape:SolidMolecular weight:428.49
![WDR5-0103 hydrochloride[890190-22-4(free base)]](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FTM%2Fthumb-webp%2FT5140.webp&w=3840&q=75)
